🟢 Moderna is trading 4.09% up today after FDA approval of first mRNA flu vaccine

Moderna is trading 4.09% up now at $63.05 after renewed attention to the FDA’s approval of mFlusiva, its first mRNA-based seasonal flu vaccine.

• Approved for adults aged 50 and older; availability is expected for the 2026–2027 flu season.
• Reuters and BioPharma Dive reported the regulatory milestone, a clear company-specific catalyst.
• Broader markets are modestly higher after July CPI data, but Moderna’s gain appears primarily tied to the vaccine approval.